Coloplast A/S Class B
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Gavin Wood
- Full Time Employees
- 16,907
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Holtedam 1 Humlebaek ZE Denmark 3050
- IPO Date
- Jan 1, 1983
- Website
- coloplast.com
- Similar Companies
- Business
- Coloplast A/S develops manufactures and markets medical devices and services for intimate healthcare needs including ostomy urology continence wound care bowel care voice and respiratory care and interventional urology; its core products encompass ostomy bags and accessories such as Sensura Mio pouches baseplates and convexity solutions; intermittent catheters including the Luja catheter; bowel management systems for transanal irrigation; voice and respiratory care devices for laryngectomy and tracheostomy patients; advanced wound dressings and biologics through subsidiaries like Kerecis; and interventional urology solutions for men's health with upcoming Intibia for women's health pending FDA approval. Founded in 1957 and headquartered in Humlebæk Denmark the company employs over 14000 people operates sales in more than 50 countries with production facilities in Denmark Hungary France China and the US and serves hospitals institutions wholesalers retailers and direct-to-consumer channels primarily in Europe North America and emerging markets. Recent developments include the presentation of its Impact4 five-year strategy in September 2025 targeting 7-8% organic revenue growth through 2030 solidification of chronic care leadership with new ostomy solutions Luja catheters US bowel care reimbursement from October 2025 and Intibia launch in 2026/27; reorganization into Chronic Care and Acute Care business units announced in August 2025; ongoing integration of the 2021 Atos Medical acquisition finalizing in 2025/26 with DKK 100 million synergies; completion of prior acquisitions like Comfort Medical Hope Medical and Rocky Medical Supply; and Global Operations Plan 7 for gross margin and cash flow improvements.
Company News
Coloplast A/S (OTCMKTS:CLPBY) Shares Climb 3.9% – Should You Buy?
Coloplast A/S (CLPBY) Q3 2026 Earnings Call Transcript
Coloplast expects Kerecis wound-care unit to return to growth in 2027, CFO says
Coloplast Might Have Found Its Bottom
Coloplast: Went 'BUY' A Bit Early
Coloplast A/S (CLPBY) Q2 2026 Earnings Call Transcript
Coloplast A/S (CLPBY) Q4 2026 Guidance Call Transcript
Comparing Coloplast A/S (OTCMKTS:CLPBY) & Bluejay Diagnostics (NASDAQ:BJDX)
Coloplast: The Market Is Throwing Away A High-Quality Compounder
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
Coloplast appoints Gavin Wood as new CEO
CLPBY or PEN: Which Is the Better Value Stock Right Now?
Reviewing OPKO Health (NASDAQ:OPK) and Coloplast A/S (OTCMKTS:CLPBY)
Coloplast A/S - Updated Financial Calendar 2025-26
Coloplast A/S (OTCMKTS:CLPBY) Shares Gap Down – What’s Next?
Coloplast A/S (CLPBY) Q1 2026 Earnings Call Transcript
Coloplast A/S - Interim Financial Report, Q1 2025/26
Coloplast A/S - Interim Financial Report, Q1 2025/26
CLPBY vs. PEN: Which Stock Is the Better Value Option?